Navigation Links
Peptimmune Announces First Close of Series D Private Financing

CAMBRIDGE, Mass., Jan. 17 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a first close of $8.2 million of a Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, as well as certain other investors, including its Chairman of the Board. The Company expects a second close in Q2/2008, which may involve an additional new investor. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.

"We are pleased with the level of continuing support from our existing investors and the opportunity to expand our syndicate," stated Thomas P. Mathers, President and CEO. "The Series D investment will provide the necessary capital to complete two clinical trials by the end of 2008: the current single ascending dose in healthy volunteers and a multiple ascending dose in multiple sclerosis patients, expected to start in Q2/08. The completion of these two studies will offer proof of principal for PI-2301, which is a second generation copolymer targeted at treating patients with relapsing and remitting multiple sclerosis."

Financing Two Clinical Trials in Multiple Sclerosis

Peptimmune is currently completing its Phase I single ascending dose study for PI-2301, a double blind placebo controlled randomized study that involves 56 healthy male volunteers who will receive the drug in eight escalating dose cohorts. Following establishment of safety at potentially therapeutic doses, the Company will initiate its first repeat dose study in multiple sclerosis patients in Q2/2008, where it will explore safety, pharmacokinetics and pharmacodynamics over eight to twelve weeks of dosing.

About PI-2301

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre-clinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. It is expected that weekly dosing administration with PI-2301 will provide greater patient convenience and tolerability over Copaxone's daily dosing administration. PI-2301 has also shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and autoimmune uveitis. Peptimmune has also introduced highly reproducible manufacturing methods that allow very strict control and characterization of PI-2301 and should provide a superior level of batch to batch consistency.

Information on Multiple Sclerosis

Over 400,000 Americans have multiple sclerosis (MS), and worldwide MS may affect over 2.5 million individuals. MS is an autoimmune disease in which the individual's immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, and Silicon Valley Bank Capital. For additional information, access our website at, or contact Dustan Bonnin at (617) 715-8043.

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Vasogen Announces 2007 Year-End Results
4. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
5. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
6. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
7. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
8. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
9. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
10. Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend
11. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
Post Your Comments:
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):